PDL BioPharma Inc

PDL BioPharma — Q3 2020 Earnings Presentation

13 slides from PDL BioPharma's earnings presentation, Nov 13, 2020

  1. Slide 1: Third Quarter 2020 Financial Results and Business Update Conference Call

    PDL Third Quarter 2020 Financial Results and Business Update Conference Call November 11, 2020 Nasdaq: PDLI

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forwardooking statements inducing POL's expectations with respect to revenues, expenses, net income and cash provided by operating aciiviies. Each of these forwardooking statements involves risks and uncertainties. Actual results may differ mater

  3. Slide 3: Strong Progress in Monetizing Assets

    Strong Progress in Monetizing Assets o Completed monetization of our operating businesses with the closing of sale of Noden in September and spin-off of LENSAR in October o Executed the sale of a basket of royalties to SWK Holdings in August o Transactions have simplified the PDL portfolio and place

  4. Slide 4: Completed Sale of Noden Pharma

    Completed Sale of Noden Pharma o Closed transaction in early September with payments to PDL of up to $52.83 million, which is $4.6 million higher than announced in July = Received $12.2 million payment on closing. = Due to receive an additional $.52 million as VAT reimbursement in 2021. = Additional

  5. Slide 5: Executed Spin-off of LENSAR

    Executed Spin-off of LENSAR o Net assets attributable to LENSAR on September 30, 2020 were $112.4 million o On October 1* effected spin-off in the form of a dividend involving the distribution of all outstanding LENSAR shares held by PDL to holders of PDL common stock o On October 24 LENSAR became a

  6. Slide 6: Reached Wellstat Settlement Agreement

    Reached Wellstat Settlement Agreement ° Announced settlement resolving the previously reported litigation relating to $44.1 million loans made to Wellstat Diagnostics in August 2013 The Wellstat Parties paid $7.5 million at signing The Wellstat Parties can pay either: = $5 million by February 10", 2

  7. Slide 7: Royalty Assets and Other Holdings

    Royalty Assets and Other Holdings o Sold Kybella®, Zalviso® and Coflex® royalties to SWK Holdings Corporation for $4.35 million in cash = Transaction may qualify for federal tax benefits under the CARES Act o PDL remaining royalty portfolio includes Glumetza®, Jentadueto® XR, Invokamet® XR and Synja

  8. Slide 8: Filing of Certificate of Dissolution

    Filing of Certificate of Dissolution o Approval of proposal to file of Certificate of Dissolution-authorized by stockholders at 2020 Annual Meeting o Board decision to file Certificate of Dissolution on January 4, 2021 o Under Delaware Law, PDL will continue its existence for a minimum of 3 years po

  9. Slide 9: Summary of Net Assets in Liquidation

    Summary of Net Assets in Liquidation o At the end of Q3 and prior to LENSAR’s spin-off, PDL’s net assets in liquidation were $501.9 million o Net assets attributable to LENSAR on September 30 were $112.4 million o Excluding LENSAR’s assets and liabilities, PDL’s net assets in liquidation were $389.5

  10. Slide 10: Condensed Consolidated Statements of Operations

    Condensed Consolidated Statements of Operations Two Months ThreeMonths Eight Months Nine Months Ended Ended Ended Ended ‘August 31, September 30, August 31, September 20, hn ousands, exceptper share amounts) 2020 13 2020 219 Product remenue, nat s zen s 5950 s Ke s 15800 Lesee revenue 703 1322 2.138

  11. Slide 11: Condensed Consolidated Statement of Net Assets

    Condensed Consolidated Statement of Net Assets (Proforma) September 30, September 30, (in thousands) 2020 2020 (Under Liquidation Basis of Accounting) (Excluding LENSAR) Assets Cash and cash equivalents s 125,736 S$ 83,035 Accounts receivable 8,323 5,894 Receivables from asset sales 39,389 39,389 No

  12. Slide 12: Condensed Royalty Asset Data

    Condensed Royalty Asset Data Assertio VB uM AcelRx KYBELLA Three Months Ended Nine Months Ended September 30, 2020 September 30, 2019 September 30, 2020 September 30, 2019 Cash Royalties Cash Royalties Cash Royalties Cash Royalties $ 15,205 $ 23,507 $ 35,222 $ 52,980 137 254 e12 748 2.219 4,574 6.57

  13. Slide 13: Questions & Answers

    PDL Questions & Answers

PDL BioPharma — Q3 2020 Earnings Presentation on 6ix